首页> 外文期刊>The British Journal of Nutrition >Human milk oligosaccharides reduce Entamoeba histolytica attachment and cytotoxicity in vitro.
【24h】

Human milk oligosaccharides reduce Entamoeba histolytica attachment and cytotoxicity in vitro.

机译:人乳寡糖在体外可减少溶血性变形杆菌的附着和细胞毒性。

获取原文
获取原文并翻译 | 示例
       

摘要

Human milk oligosaccharides (HMO), complex sugars that are highly abundant in breast milk, block viral and bacterial attachment to the infant's intestinal epithelium and lower the risk of infections. We hypothesised that HMO also prevent infections with the protozoan parasite Entamoeba histolytica, as its major virulence factor is a lectin that facilitates parasite attachment and cytotoxicity and binds galactose (Gal) and N-acetyl-galactosamine. HMO contain Gal, are only minimally digested in the small intestine and reach the colon, the site of E. histolytica infection. The objective of the present study was to investigate whether HMO reduce E. histolytica attachment and cytotoxicity. Our in vitro results show that physiological concentrations of isolated, pooled HMO detach E. histolytica by more than 80%. In addition, HMO rescue E. histolytica-induced destruction of human intestinal epithelial HT-29 cells in a dose-dependent manner. The cytoprotective effects were structure-specific. Lacto-N-tetraose with its terminal Gal rescued up to 80% of the HT-29 cells, while HMO with fucose alpha1-2-linked to the terminal Gal had no effect. Galacto-oligosaccharides (GOS), which also contain terminal Gal and are currently added to infant formula to mimic some of the beneficial effects of HMO, completely abolished E. histolytica attachment and cytotoxicity at 8 mg/ml. Although our results need to be confirmed in vivo, they may provide one explanation for why breast-fed infants are at lower risk of E. histolytica infections. HMO and GOS are heat tolerant, stable, safe and in the case of GOS, inexpensive, which could make them valuable candidates as alternative preventive and therapeutic anti-amoebic agents. Copyright copyright The Authors 2012.
机译:人乳寡糖(HMO)是母乳中高度丰富的复合糖,可阻止病毒和细菌附着在婴儿的肠上皮上,并降低感染的风险。我们假设HMO还可以防止原生动物寄生虫组织变形虫Entamoeba histolytica的感染,因为其主要毒力因子是一种凝集素,可促进寄生虫的附着和细胞毒性,并结合半乳糖(Gal)和N-乙酰半乳糖胺。 HMO含有Gal,仅在小肠中被最少消化,并到达结肠,即溶组织性大肠杆菌的感染部位。本研究的目的是研究HMO是否能降低溶血性大肠杆菌的附着和细胞毒性。我们的体外结果表明,分离的,合并的HMO的生理浓度使溶组织性大肠杆菌脱离了80%以上。此外,HMO以剂量依赖性方式拯救了溶血性大肠杆菌引起的人肠上皮HT-29细胞破坏。细胞保护作用是结构特异性的。带有Gal末端的Lacto-N-四糖挽救了80%的HT-29细胞,而具有连接到Gal末端的岩藻糖α1-2的HMO没有作用。低聚半乳糖(GOS),也包含末端Gal,目前已添加到婴儿配方食品中,以模仿HMO的某些有益作用,完全消除了8 mg / ml的溶血性大肠杆菌的附着和细胞毒性。尽管我们的结果需要在体内得到证实,但它们可能为为什么母乳喂养的婴儿患溶组织性大肠杆菌感染的风险较低提供了一种解释。 HMO和GOS具有耐热性,稳定性,安全性,并且就GOS而言,价格便宜,这使其成为有价值的候选替代性预防和治疗性抗阿米巴剂。著作权The Authors 2012。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号